Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UDI report: FDA needs to educate firms on program

This article was originally published in The Silver Sheet

Executive Summary

FDA needs to explain more clearly to device companies why they need to submit certain information to support a unique device identifier system, a recent UDI pilot test found. FDA contracted with consulting firm GHX to conduct and assess FDA's six-week UDI prototype pilot. Six device firms - including Becton Dickinson (BD), Covidien and GE Healthcare - and five user institutions participated in the pilot. The manufacturers entered data on hundreds of devices. Based on feedback collected by GHX, the consulting firm advised the agency to develop clearer explanations and scenarios about why each piece of information requested from firms to support UDI is necessary to meet FDA requirements and address patient safety issues
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT036435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel